Background: Long-term subjective outcomes of prostate cancer are relatively unknown. The Oregon Urology Institute (OUI) has been collecting subjective functional outcome data to help determine the long-term subjective outcomes of prostatectomy vs radiation therapy.
Methods: Patients treated at OUI completed interval post-treatment questionnaires that assessed: urinary, bowel, sexual, and hormonal function, and overall treatment satisfaction. Two cohorts were established: prostatectomy vs radiation. Results from each cohort were compared and analyzed with a linear mixed effect model.
Results: Our longitudinal dataset includes a prostatectomy cohort of 410 patients and radiation therapy cohort of 416 patients surveyed at the 3-month interval, but the number of patients decreased after each time interval (ie 3, 6, 9, and 12 months and then annually for up till 14 years post-treatment). Urinary and sexual functional scores decreased by 4% and 8% after radiation, whereas prostatectomy had a 5% and 13% increase over time post-treatment, respectively. Over time, patients treated with prostatectomy were found to be more satisfied with the outcome of their treatment than patients receiving radiation therapy.
Conclusion: Prostatectomy and radiation therapy had impacts on quality of life measurements that emphasize the importance of making the best-informed decision in each unique situation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/00031348221148367 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Stereotactic Body Therapy for Urologic Cancers-What the Urologist Needs to Know.
Life (Basel)
December 2024
Department of Surgery, Peter MacCallum Cancer Centre, The University of Melbourne, Parkville, VIC 3052, Australia.
Background: stereotactic ablative body radiotherapy (SABR) is a disruptive radiation therapy technique which is increasingly used for the treatment of urologic cancers. The aim of this narrative review is to provide an overview on the current landscape of SABR in urologic cancers and highlight advancements on the horizon.
Methods: a narrative review of the contemporary role of SABR in urologic cancers is conducted.
Evidences on the Use of Hypofractionation in Postoperative/Salvage Radiotherapy for Prostate Cancer: Systematic Review of the Literature and Recent Developments.
Cancers (Basel)
December 2024
Radiation Oncology Department, Centre Leon Berard, 69373 Lyon, France.
Background: Radical prostatectomy (RP) is one possible curative treatment for localized prostate cancer. Despite that, up to 40% of patients will later relapse. Currently, post-operative radiotherapy (PORT) courses deliver 1.
View Article and Find Full Text PDFImpact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta-analysis.
BJU Int
January 2025
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Objective: To perform a systematic review and meta-analysis to assess the relationship between intraprostatic maximum standardised uptake value (SUV) of the dominant prostatic lesion as measured on preoperative prostate-specific membrane antigen (PSMA) positron emission tomography (PET) with radical prostatectomy International Society of Urological Pathology (ISUP) Grade Group, pathological tumour (pT) staging, and biochemical recurrence (BCR).
Methods: Prostate-specific membrane antigen PET may offer non-invasive assessment of histopathological and oncological outcomes before definitive treatment. SUV of the dominant lesion has been explored as a prognostic biomarker.
Outcomes and Toxicities After Treatment for Men Diagnosed With Localized Prostate Cancer in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis.
Adv Radiat Oncol
January 2025
Department of Medical Imaging, Faculty of Allied Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.
Purpose: Current management for clinically localized prostate cancer in low- and middle-income countries (LMICs) includes surgery, external beam radiation therapy (EBRT), and brachytherapy either alone or in combination, with plus or minus hormone therapy. The toxicity profiles and oncological outcomes of these treatment modalities vary. This systematic review and meta-analysis aimed to determine the prevalence of treatment-related outcomes and toxicities for men diagnosed with localized prostate cancer in LMICs.
View Article and Find Full Text PDFEarly outcomes following local salvage treatment with MRI-assisted low-dose rate brachytherapy (MARS) for MRI-visible postsurgical bed recurrences and focal intraprostatic recurrences.
Brachytherapy
January 2025
Department of Genitourinary Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Background: To determine outcomes of MRI-assisted radiosurgery (MARS) for salvage brachytherapy using the radioisotope Pd after various upfront treatments including surgery, external beam radiotherapy, and brachytherapy.
Methods: We retrospectively reviewed data for patients who underwent salvage MARS for intraprostatic lesions or prostate bed recurrences from 2016 to 2022. Biochemical recurrence, prostate cancer-specific, and overall survival, and the cumulative incidences of toxicities, were determined by Kaplan-Meier estimates.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!